Yiming Cell Biotechnology Co., Ltd, known as Ubrigene Biosciences Inc., a leading gene and cell therapy contract development and manufacturing organization (CDMO) based in Beijing, has reportedly raised RMB 150 million (USD 21.8 million) in a Series C+ financing round. The funding was led by Guotai Junan Innovation Investment and Jinan Industrial Development Investment, with participation from FOF Capital. The proceeds will be allocated towards the company’s globalization strategy, cutting-edge technology development, and the establishment of a global CGT CDMO whole industry chain platform.
Ubrigene’s Global Facilities and R&D Centers
Founded in 2015, Ubrigene has established a strong presence in the gene and cell therapy space with GMP-compliant facilities in Suzhou and Jinan, China. Additionally, the company has CMC research and development (R&D) centers in the United States and Canada, showcasing its commitment to global standards and innovation in the field.
Globalization and Industry Chain Development
The investment will support Ubrigene’s efforts to expand its global footprint and enhance its technology capabilities, positioning the company as a key player in the global CGT CDMO industry. This funding round underscores the confidence of investors in Ubrigene’s potential to drive innovation and provide comprehensive solutions across the gene and cell therapy value chain.-Fineline Info & Tech
